Vaxil Bio Intangible Assets
Intangible Assets of Vaxil Bio (VXL.V) as of Nov 3, 2026.
Get this data via API
Financial Data API
Intangible Assets
-CAD
Last updated:
Intangible Assets of Vaxil Bio is 2026 - CAD. Intangible Assets of Vaxil Bio was 2025 - CAD. It decreases by % lower compared to the previous year.
The Vaxil Bio Intangible Assets history
3 Years
10 Years
25 Years
Max
Intangible Assets
Date
Intangible Assets
Jan 1, 2018
0.00 CAD
Jan 1, 2019
0.00 CAD
Jan 1, 2020
0.00 CAD
Jan 1, 2021
0.00 CAD
Jan 1, 2022
0.00 CAD
Jan 1, 2023
0.00 CAD
Jan 1, 2024
0.00 CAD
Jan 1, 2025
0.00 CAD
| YEAR | Intangible Assets | YoY |
|---|---|---|
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — | |
| 0.00CAD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Vaxil Bio Stock analysis
What does Vaxil Bio do? Vaxil Bio Ltd is a biotechnology company based in Toronto, Canada, specializing in immunotherapy for cancer and infectious diseases. Listed on March 2, 2011, the firm develops novel treatments using a platform based on signal peptides. Its advanced product, ImMucin, is a vaccine derived from MUC1 signal peptides that completed Phase I/II trials for multiple myeloma. The company also holds candidates for COVID-19 and tuberculosis vaccines, as well as monoclonal antibodies for oncology and infectious diseases. Additionally, Vaxil Bio has initiated a pre-clinical program for a drug delivery polymer targeting E-selectin, licensed from BGN Technologies, aiming to create targeted therapies against critical disease targets. Vaxil Bio is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Vaxil Bio stock
On Eulerpool you can find the complete historical development of Intangible Assets Vaxil Bio since 2006 – with annual values, charts, and detailed analysis.
Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.
Intangible Assets's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Vaxil Bio historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — Vaxil Bio
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — Vaxil Bio
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth